These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 17612756)

  • 1. Reduced risk of new-onset diabetes with trandolapril/verapamil-SR in patients with the metabolic syndrome.
    Cardiovasc J Afr; 2007; 18(3):190. PubMed ID: 17612756
    [No Abstract]   [Full Text] [Related]  

  • 2. Antihypertensive properties of a high-dose combination of trandolapril and verapamil-SR.
    Messerli F; Frishman WH; Elliott WJ; Bacher PH; Pepine CJ
    Blood Press Suppl; 2007 Mar; 1():6-9. PubMed ID: 17566313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trandolapril / verapamil SR combination reverses drug-induced new-onset diabetes.
    Cardiovasc J Afr; 2008; 19(2):118. PubMed ID: 18516363
    [No Abstract]   [Full Text] [Related]  

  • 4. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
    Cooper-Dehoff R; Cohen JD; Bakris GL; Messerli FH; Erdine S; Hewkin AC; Kupfer S; Pepine CJ;
    Am J Cardiol; 2006 Oct; 98(7):890-4. PubMed ID: 16996868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of trandolapril and its fixed-dose combination with verapamil on circulating adhesion molecules levels in hypertensive patients with type 2 diabetes.
    Rubio-Guerra AF; Vargas-Robles H; Vargas-Ayala G; Rodriguez-Lopez L; Escalante-Acosta BA
    Clin Exp Hypertens; 2008 Oct; 30(7):682-8. PubMed ID: 18855271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fixed combination verapamil SR/trandolapril.
    Dooley M; Goa KL
    Drugs; 1998 Nov; 56(5):837-44; discussion 845-6. PubMed ID: 9829157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factor assessment for new onset diabetes: literature review.
    Bakris G; Stockert J; Molitch M; Zhou Q; Champion A; Bacher P; Sowers J;
    Diabetes Obes Metab; 2009 Mar; 11(3):177-87. PubMed ID: 18564174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Usefulness of long-acting Ca antagonist in hypertensive patients with metabolic syndrome].
    Takishita S
    Nihon Rinsho; 2006 Dec; 64 Suppl 9():607-10. PubMed ID: 17458290
    [No Abstract]   [Full Text] [Related]  

  • 9. Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension.
    Reynolds NA; Wagstaff AJ; Keam SJ
    Drugs; 2005; 65(13):1893-914. PubMed ID: 16114984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.
    Bangalore S; Messerli FH; Cohen JD; Bacher PH; Sleight P; Mancia G; Kowey P; Zhou Q; Champion A; Pepine CJ;
    Am Heart J; 2008 Aug; 156(2):241-7. PubMed ID: 18657652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose verapamil-trandolapril induced rhabdomyolysis and acute renal failure.
    Gokel Y; Paydas S; Duru M
    Am J Emerg Med; 2000 Oct; 18(6):738-9. PubMed ID: 11043636
    [No Abstract]   [Full Text] [Related]  

  • 12. The relationship between antihypertensive combination therapies comprising diuretics and/or beta-blockers and the risk of new-onset diabetes: a retrospective longitudinal cohort study.
    Liou YS; Ma T; Tien L; Lin CM; Jong GP
    Hypertens Res; 2009 Jun; 32(6):496-9. PubMed ID: 19390541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The choice of antihypertensive therapy in patients with the metabolic syndrome--time to change recommendations?
    Hilgers KF; Mann JF
    Nephrol Dial Transplant; 2008 Nov; 23(11):3389-91. PubMed ID: 18687734
    [No Abstract]   [Full Text] [Related]  

  • 14. [Vascular agents can prevent type 2 diabetes].
    Nilsson P
    Lakartidningen; 2003 Feb; 100(7):528-30. PubMed ID: 12640987
    [No Abstract]   [Full Text] [Related]  

  • 15. Treating hypertension by rational use of diuretics: results of the Russian ARGUS-2 Study.
    Kobalava ZD; Kotovskaya YV; Villevalde SV; Moiseev VS;
    Curr Med Res Opin; 2009 Sep; 25(9):2229-37. PubMed ID: 19622008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population.
    Mancia G; Bombelli M; Facchetti R; Madotto F; Corrao G; Trevano FQ; Giannattasio C; Grassi G; Sega R
    J Hypertens; 2008 Aug; 26(8):1602-11. PubMed ID: 18622239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic syndrome: treatment of hypertensive patients.
    Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M
    Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular drugs as antidiabetic agents: evidence for the prevention of type 2 diabetes.
    Macfarlane DP; Paterson KR; Fisher M
    Diabetes Obes Metab; 2008 Jul; 10(7):533-44. PubMed ID: 18248492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stemming the obesity-diabetes epidemic: lifestyle changes and therapeutics.
    Schrier RW; Bogaert YE
    Nat Clin Pract Nephrol; 2008 Sep; 4(9):486-7. PubMed ID: 18665143
    [No Abstract]   [Full Text] [Related]  

  • 20. ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients.
    Zheng S; Nath V; Coyne DW
    Am J Nephrol; 2007; 27(5):522-9. PubMed ID: 17700014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.